CCL2 and lung cancer: Therapeutic CCL2-blockade also decreased the recruitment of MDSCs in both the blood and tumors collected from lung cancer-bearing mice (159) and resulted in increased CD4+ and CD8+ T cell infiltration of tumors, higher production of IFNγ, and improved survival of tumor-bearing mice.